News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Garland J. Scott
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/29/2022 |
4
| Garland J. Scott (Director) has filed a Form 4 on ALX ONCOLOGY HOLDINGS INC|
Txns:
| Granted 24,009 options to buy
@ $10.07, valued at
$241.8k
|
|
| 06/23/2022 |
4
| Garland J. Scott (Director) has filed a Form 4 on Day One Biopharmaceuticals, Inc.|
Txns:
| Granted 28,700 options to buy
@ $16.29, valued at
$467.5k
|
|
| 06/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/18/2021 |
4
| Garland J. Scott (Director) has filed a Form 4 on Day One Biopharmaceuticals, Inc.|
Txns:
| Granted 48,072 options to buy
@ $24.65, valued at
$1.2M
|
|
| 06/14/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/04/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/02/2020 |
4
| Garland J. Scott (President and CEO) has filed a Form 4 on PORTOLA PHARMACEUTICALS INC|
Txns:
| Disposed/sold 24,529 shares
@ $18, valued at
$441.5k
Granted 1,173 shares
@ $8.36, valued at
$9.8k
Disposed/sold 1,173 shares
@ $18, valued at
$21.1k
Disposed/sold 100,000 rights
@ $0
Disposed/sold 50,000 rights
@ $0
Disposed/sold 200,000 options to buy
@ $12.79, valued at
$2.6M
Disposed/sold 100,000 options to buy
@ $12.79, valued at
$1.3M
Disposed/sold 370,400 options to buy
@ $0
Disposed/sold 153,399 restricted stock units
@ $0 |
|
| 02/26/2020 |
4
| Garland J. Scott (President and CEO) has filed a Form 4 on PORTOLA PHARMACEUTICALS INC|
Txns:
| Granted 150,000 rights
@ $0 |
|
| 02/04/2020 |
4
| Garland J. Scott (President and CEO) has filed a Form 4 on PORTOLA PHARMACEUTICALS INC|
Txns:
| Granted 50,000 shares
@ $0
Paid exercise price by delivering 5,623 shares
@ $12.89, valued at
$72.5k
Granted 200,000 options to buy
@ $12.79, valued at
$2.6M
|
|
| 11/04/2019 |
4
| Garland J. Scott (President and CEO) has filed a Form 4 on PORTOLA PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 21,549 shares
@ $29.84, valued at
$643k
|
|
| 06/07/2019 |
4
| Garland J. Scott (Director) has filed a Form 4 on Karyopharm Therapeutics Inc.|
Txns:
| Granted 25,000 options to buy
@ $5.43, valued at
$135.8k
|
|
| 02/04/2019 |
4
| Garland J. Scott (President and CEO) has filed a Form 4 on PORTOLA PHARMACEUTICALS INC|
Txns:
| Granted 30,100 shares
@ $0
Granted 120,400 options to buy
@ $27.1, valued at
$3.3M
|
|
| 10/31/2018 |
4
| Garland J. Scott (President and CEO) has filed a Form 4 on PORTOLA PHARMACEUTICALS INC|
Txns:
| Granted 125,000 shares
@ $0
Granted 250,000 options to buy
@ $19.69, valued at
$4.9M
|
|
| 06/20/2018 |
4
| Garland J. Scott (Director) has filed a Form 4 on Karyopharm Therapeutics Inc.|
Txns:
| Granted 17,000 options to buy
@ $18.8, valued at
$319.6k
|
|
| 06/16/2017 |
4
| Garland J. Scott (Director) has filed a Form 4 on Karyopharm Therapeutics Inc.|
Txns:
| Granted 17,000 options to buy
@ $9.18, valued at
$156.1k
|
|
| 09/02/2016 |
4
| Garland J. Scott (SVP & Chief Commercial Officer) has filed a Form 4 on Relypsa Inc|
Txns:
| Granted 4,167 shares
@ $0
Unknown transaction of 2,470 shares
@ $32, valued at
$79k
Disposed/sold 16,042 shares
@ $32, valued at
$513.3k
Granted 16,667 options to buy
@ $18.87, valued at
$314.5k
Disposed/sold 25,000 options to buy
@ $18.87, valued at
$471.8k
Disposed/sold 100,000 options to buy
@ $21.36, valued at
$2.1M
Disposed/sold 35,000 options to buy
@ $28.38, valued at
$993.3k
|
|
| 08/17/2016 |
4
| Garland J. Scott (SVP & Chief Commercial Officer) has filed a Form 4 on Relypsa Inc|
Txns:
| Paid exercise price by delivering 705 shares
@ $31.89, valued at
$22.5k
|
|
| 06/17/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 06/07/2016 |
4
| Garland J. Scott (SVP & Chief Commercial Officer) has filed a Form 4 on Relypsa Inc|
Txns:
| Granted 2,083 shares
@ $0
Paid exercise price by delivering 783 shares
@ $19.96, valued at
$15.6k
Granted 8,333 options to buy
@ $18.87, valued at
$157.2k
|
|
| 11/10/2015 |
4
| Garland J. Scott (SVP & Chief Commercial Officer) has filed a Form 4 on Relypsa Inc|
Txns:
| Granted 6,250 shares
@ $0 |
|
| 08/12/2015 |
4
| Garland J. Scott (SVP & Chief Commercial Officer) has filed a Form 4 on Relypsa Inc|
Txns:
| Granted 7,500 shares
@ $0
Granted 35,000 options to buy
@ $28.38, valued at
$993.3k
|
|
| 05/26/2015 |
4
| Garland J. Scott (Director) has filed a Form 4 on Karyopharm Therapeutics Inc.|
Txns:
| Granted 10,000 options to buy
@ $26.15, valued at
$261.5k
|
|
| 11/18/2014 |
4
| Garland J. Scott (SVP & Chief Commercial Officer) has filed a Form 4 on Relypsa Inc|
Txns:
| Granted 100,000 options to buy
@ $21.36, valued at
$2.1M
|
|
| 11/12/2014 |
4
| Garland J. Scott (Director) has filed a Form 4 on Karyopharm Therapeutics Inc.|
Txns:
| Granted 20,000 options to buy
@ $43.3, valued at
$866k
|
|
| 09/19/2013 |
4
| Garland J. Scott (EVP & Chief Commerical Officer) has filed a Form 4 on EXELIXIS, INC.|
Txns:
| Granted 150,000 options to buy
@ $5.51, valued at
$826.5k
|
|
| 09/21/2012 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 10/24/2011 |
4
| Garland J. Scott (EVP & Chief Commerical Officer) has filed a Form 4 on EXELIXIS INC|
Txns:
| Granted 200,000 options to buy
@ $5.47, valued at
$1.1M
|
|
|
|